IKT
NASDAQ · Biotechnology
Inhibikase Therapeutics Inc
$1.76
-0.10 (-5.38%)
Open$1.85
Previous Close$1.86
Day High$1.85
Day Low$1.75
52W High$2.27
52W Low$1.33
Volume—
Avg Volume644.5K
Market Cap245.58M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,491.5% upside
Current
$1.76
$1.76
Target
$28.01
$28.01
$19.41
$28.01 avg
$39.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 78.22M | 74.95M | 61.90M |
| Net Income | 4.38M | 5.16M | 3.75M |
| Profit Margin | 5.6% | 6.9% | 6.1% |
| EBITDA | 7.32M | 7.08M | 6.90M |
| Free Cash Flow | 4.21M | 5.04M | 4.89M |
| Rev Growth | +8.7% | +15.3% | -5.1% |
| Debt/Equity | 0.35 | 0.45 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |